On Dec. 2, 2020, Eli Lilly announced that the U.S. government had purchased 650,000 additional doses of the company’s neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement was for $812.5 million and the doses to be delivered through January 31, 2021, with at least 350,000 of the additional doses delivered in December 2020.

Bamlanivimab received emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.